We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Turning Point Therapeutics, Inc. (“Turning Point” or the “Company”) (NASDAQ: TPTX), in connection with the proposed acquisition of the Company by Bristol-Myers Squibb Company (NYSE: BMY) via a tender offer.  Under the terms of the merger agreement, the Company’s shareholders will receive $76.00 in cash for each share of Turning Point common stock owned.  The transaction is valued at approximately $4.1 billion.

Weiss Law is investigating whether (i) Turning Point’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $76.00 per-share merger consideration adequately compensates Turning Point’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, the merger consideration is below the $93.00 median price target set by analysts, and at least one analyst set a price target for the Company of $175 per share, $99.00 above the per-share merger consideration.